title: Heparanase induces VEGF C and facilitates tumor lymphangiogenesis.
abstract: Heparanase is an endoglycosidase that specifically cleaves heparan sulfate side chains, a class of glycosaminoglycans abundantly present in the extracellular matrix and on the cell surface. Heparanase activity is strongly implicated in tumor angiogenesis and metastasis attributed to remodeling of the subepithelial and subendothelial basement membranes. We hypothesized that similar to its proangiogenic capacity, heparanase is also engaged in lymphangiogenesis and utilized the D2-40 monoclonal antibody to study lymphangiogenesis in tumor specimens obtained from 65 head and neck carcinoma patients. Lymphatic density was analyzed for association with clinical parameters and heparanase staining. We provide evidence that lymphatic vessel density (LVD) correlates with head and neck lymph node metastasis (N-stage, p = 0.007) and inversely correlates with tumor cell differentiation (p = 0.007). Notably, heparanase staining correlated with LVD (p = 0.04) and, moreover, with VEGF C levels (p = 0.01). We further demonstrate that heparanase overexpression by epidermoid, breast, melanoma and prostate carcinoma cells induces a 3- to 5-fold elevation in VEGF C expression in vitro and facilitates tumor xenograft lymphangiogenesis in vivo, whereas heparanase gene silencing was associated with decreased VEGF C levels. These findings suggest that heparanase plays a unique dual role in tumor metastasis, facilitating tumor cell invasiveness and inducing VEGF C expression, thereby increasing the density of lymphatic vessels that mobilize metastatic cells.
authors.affiliation: Cancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
authors.forename: Victoria
authors.initials: V
authors.lastname: Cohen-Kaplan
authors.forename: Inna
authors.initials: I
authors.lastname: Naroditsky
authors.forename: Anna
authors.initials: A
authors.lastname: Zetser
authors.forename: Neta
authors.initials: N
authors.lastname: Ilan
authors.forename: Israel
authors.initials: I
authors.lastname: Vlodavsky
authors.forename: Ilana
authors.initials: I
authors.lastname: Doweck
mesh_terms: D000368:Aged; D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005966:Glucuronidase / Q000235:genetics / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D042583:Lymphangiogenesis; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009367:Neoplasm Staging; D015996:Survival Rate; D042582:Vascular Endothelial Growth Factor C / Q000235:genetics / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays; D000099175:Heparanase
chemical_list: D005966:Glucuronidase; D042582:Vascular Endothelial Growth Factor C; D000099175:Heparanase
references.citation: J Clin Invest. 2004 Apr;113(7):1040-50
references.pmid: 15057311
references.citation: Semin Thromb Hemost. 2007 Jul;33(5):557-68
references.pmid: 17629854
references.citation: Pathophysiol Haemost Thromb. 2006;35(1-2):116-27
references.pmid: 16855356
references.citation: Lab Invest. 2003 May;83(5):613-22
references.pmid: 12746471
references.citation: Am J Pathol. 1988 Feb;130(2):393-400
references.pmid: 3277442
references.citation: Clin Cancer Res. 2005 Nov 15;11(22):7995-8005
references.pmid: 16299228
references.citation: Nat Med. 2001 Feb;7(2):192-8
references.pmid: 11175850
references.citation: Cancer Cell. 2002 Apr;1(3):219-27
references.pmid: 12086857
references.citation: Biochem Biophys Res Commun. 2005 May 27;331(1):175-80
references.pmid: 15845375
references.citation: Cancer Res. 2003 Dec 15;63(24):8749-56
references.pmid: 14695190
references.citation: Int J Cancer. 2001 Sep 20;95(5):295-301
references.pmid: 11494228
references.citation: Cancer Res. 1983 Jun;43(6):2704-11
references.pmid: 6601984
references.citation: Nat Med. 1999 Jul;5(7):793-802
references.pmid: 10395325
references.citation: Lab Invest. 2004 Oct;84(10):1289-304
references.pmid: 15286661
references.citation: J Cell Mol Med. 2007 May-Jun;11(3):427-52
references.pmid: 17635638
references.citation: Neoplasia. 2006 Dec;8(12):1055-61
references.pmid: 17217623
references.citation: Science. 1983 May 6;220(4597):611-3
references.pmid: 6220468
references.citation: J Thromb Haemost. 2006 Nov;4(11):2443-51
references.pmid: 16970801
references.citation: Cancer Res. 2003 Apr 15;63(8):1920-6
references.pmid: 12702584
references.citation: FASEB J. 2005 Feb;19(2):211-21
references.pmid: 15677344
references.citation: Cell Tissue Res. 2003 Oct;314(1):167-77
references.pmid: 12883995
references.citation: Int J Cancer. 2006 Oct 15;119(8):1755-60
references.pmid: 16557570
references.citation: J Natl Cancer Inst. 2004 Aug 18;96(16):1219-30
references.pmid: 15316057
references.citation: Am J Pathol. 2005 Mar;166(3):913-21
references.pmid: 15743802
references.citation: Ann Oncol. 2003 Oct;14(10):1505-10
references.pmid: 14504050
references.citation: Chem Biol. 2005 Mar;12(3):267-77
references.pmid: 15797210
references.citation: Cancer. 2001 Aug 1;92(3):556-68
references.pmid: 11505400
references.citation: Cancer Res. 2002 Mar 1;62(5):1315-20
references.pmid: 11888898
references.citation: Gynecol Obstet Invest. 2003;56(2):77-82
references.pmid: 12904690
references.citation: Cancer Res. 2003 Nov 15;63(22):7733-41
references.pmid: 14633698
references.citation: Int J Cancer. 2006 Apr 1;118(7):1609-17
references.pmid: 16217746
references.citation: Clin Cancer Res. 2001 May;7(5):1299-305
references.pmid: 11350898
references.citation: Head Neck. 2001 Feb;23(2):147-59
references.pmid: 11303632
references.citation: Curr Pharm Des. 2007;13(20):2057-73
references.pmid: 17627539
references.citation: J Cell Sci. 2004 May 1;117(Pt 11):2249-58
references.pmid: 15126626
references.citation: Cancer Res. 2006 Feb 1;66(3):1455-63
references.pmid: 16452201
references.citation: J Surg Oncol. 2004 Sep 15;87(4):174-81
references.pmid: 15334632
references.citation: Int J Biochem Cell Biol. 2006;38(12):2018-39
references.pmid: 16901744
references.citation: Clin Cancer Res. 2001 Mar;7(3):462-8
references.pmid: 11297234
references.citation: Differentiation. 2006 Jun;74(5):235-43
references.pmid: 16759289
references.citation: Gynecol Oncol. 2007 Oct;107(1):45-51
references.pmid: 17604828
references.citation: Cancer Res. 2003 Dec 15;63(24):8821-6
references.pmid: 14695198
references.citation: Breast Cancer Res Treat. 2007 Jul;104(1):13-9
references.pmid: 17004106
references.citation: Cancer. 2004 Sep 1;101(5):973-8
references.pmid: 15329906
references.citation: J Pathol. 2005 Jun;206(2):170-7
references.pmid: 15846845
references.citation: Mini Rev Med Chem. 2004 Aug;4(6):693-702
references.pmid: 15279603
references.citation: Clin Cancer Res. 2006 Dec 1;12(23):6865-8
references.pmid: 17145802
references.citation: FASEB J. 2001 Jul;15(9):1661-3
references.pmid: 11427519
references.citation: Br J Pharmacol. 2007 May;151(1):1-14
references.pmid: 17339837
references.citation: Biochem Biophys Res Commun. 2003 Sep 5;308(4):885-91
references.pmid: 12927802
references.citation: Biochemistry. 1989 Feb 21;28(4):1737-43
references.pmid: 2541764
references.citation: Blood. 2006 May 1;107(9):3609-16
references.pmid: 16384929
references.citation: Curr Med Chem. 2006;13(18):2101-11
references.pmid: 16918340